Citigroup Inc Rubius Therapeutics, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.14 - $0.31 $7 - $17	56 Added 4.35%	1,342 $0
Q3 2022 Nov 10, 2022	SELL	$0.46 - $1.29 $318 - $892	-692 Reduced 34.98%	1,286 $1,000
Q2 2022 Aug 10, 2022	SELL	$0.79 - $5.98 $23,859 - $180,607	-30,202 Reduced 93.85%	1,978 $2,000
Q1 2022 May 12, 2022	SELL	$4.25 - $10.4 $446,976 - $1.09 Million	-105,171 Reduced 76.57%	32,180 $177,000
Q4 2021 Feb 10, 2022	BUY	$9.68 - $17.74 $410,432 - $752,175	42,400 Added 44.65%	137,351 $1.33 Million
Q3 2021 Nov 10, 2021	BUY	$17.6 - $25.91 $1.67 Million - $2.46 Million	94,951 New	94,951 $1.7 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.